Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab′)2 fragments
Identifieur interne : 000423 ( Main/Exploration ); précédent : 000422; suivant : 000424Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab′)2 fragments
Auteurs : RBID : ISTEX:259_1990_Article_BF00812361.pdfEnglish descriptors
Abstract
Six European nuclear medicine centres per formed immunoscintigraphy first retrospectively in 34 patients using indium-111-labelled carcinoembryonic antigen (CEA)-specific and/or 19-9 F(ab')2 fragments. Results for sensitivity and specificity in tumour sites were 94% and 87%, respectively, for the pelvis and 73% and 100% for the extrahepatic abdomen. A second prospective series concerned 58 other patients previously operated on for colorectal adenocarcinoma (27 colon, 31 rectum). Two-thirds of these patients had a suspected recurrence signalled by an isolated rise in tumour markers, and 46 patients examined by immunoscintigraphy, X-ray computed tomography and ultrasonography were found to have a recurrence (a total of 62 tumour sites). Sensitivity and specificity with immunoscintigraphy were 90% and 97%, respectively, for the pelvis and 62% and 95% for the extrahepatic abdomen. For 29 patients injected with CEA-specific fragments, sensitivity was 90% and specificity 94% for the pelvis. For 25 patients injected with 19-9 fragments, pelvic sensitivity and specificity were 80% and 100%, respectively, whereas sensitivity for the extrahepatic abdomen was only 29% since several cases of peritoneal carcinosis were not visualized. In the prospective series, comparison of the three imaging techniques for all tumour sites (including liver and in 5 cases thorax) gave a sensitivity and specificity of 82% and 91 %, respectively, for immunoscintigraphy, 52% and 95% for X-ray computed tomography and 59% and 100% for ultrasonography. These results thus confirm the advantage of using111In-labelled CEA-specific or 19-9 to visualize and localize recurrences of colorectal cancer.
DOI: 10.1007/BF00812361
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab′)2 fragments</title><author><name>A. Chetanneau</name><affiliation wicri:level="3"><mods:affiliation>Centre René Gauducheau and INSERM Research Unit 211, Quai Moncousu, F-44035, Nantes, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre René Gauducheau and INSERM Research Unit 211, Quai Moncousu, F-44035, Nantes</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name>R. P. Baum</name><affiliation wicri:level="1"><mods:affiliation>J.W. Goethe University Hospital, Theodor-Stern-Kai 7, D-6000, Frankfurt/Main 70, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>J.W. Goethe University Hospital, Theodor-Stern-Kai 7, D-6000, Frankfurt/Main 70</wicri:regionArea><wicri:noRegion>Frankfurt/Main 70</wicri:noRegion><wicri:noRegion>Frankfurt/Main 70</wicri:noRegion></affiliation></author><author><name>P. A. Lehur</name><affiliation wicri:level="3"><mods:affiliation>Centre René Gauducheau and INSERM Research Unit 211, Quai Moncousu, F-44035, Nantes, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre René Gauducheau and INSERM Research Unit 211, Quai Moncousu, F-44035, Nantes</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name>J. C. Liehn</name><affiliation wicri:level="3"><mods:affiliation>Institut J. Godinot, B.P. 171, F-51056, Reims, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut J. Godinot, B.P. 171, F-51056, Reims</wicri:regionArea><placeName><region type="region" nuts="2">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name>A. C. Perkins</name><affiliation wicri:level="1"><mods:affiliation>Queen's Medical Centre, University Hospital, NG7 2UH, Nottingham, UK</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Queen's Medical Centre, University Hospital, NG7 2UH, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author><author><name>R. Bares</name><affiliation wicri:level="3"><mods:affiliation>Department of Nuclear Medicine, Technical University, Pauwelsstrasse 30, D-5100, Aachen, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Nuclear Medicine, Technical University, Pauwelsstrasse 30, D-5100, Aachen</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Aix-la-Chapelle</settlement></placeName></affiliation></author><author><name>P. Bourguet</name><affiliation wicri:level="1"><mods:affiliation>Centre E. Marquis, 2 rue H. Le Guilloux, F-35033, Rennes, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre E. Marquis, 2 rue H. Le Guilloux, F-35033, Rennes</wicri:regionArea><wicri:noRegion>35033, Rennes</wicri:noRegion><wicri:noRegion>Rennes</wicri:noRegion></affiliation></author><author><name>J. Y. Herry</name><affiliation wicri:level="3"><mods:affiliation>Centre E. Marquis, 2 rue H. Le Guilloux, F-35033, Rennes, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre E. Marquis, 2 rue H. Le Guilloux, F-35033, Rennes</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name>J. C. Saccavini</name><affiliation wicri:level="3"><mods:affiliation>CIS Bioindustrie, B.P. 32, F-91191, Gif sur Yvette, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CIS Bioindustrie, B.P. 32, F-91191, Gif sur Yvette</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Gif sur Yvette</settlement></placeName></affiliation></author><author><name>J. F. Chatal</name><affiliation wicri:level="3"><mods:affiliation>Centre René Gauducheau and INSERM Research Unit 211, Quai Moncousu, F-44035, Nantes, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre René Gauducheau and INSERM Research Unit 211, Quai Moncousu, F-44035, Nantes</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1990_Article_BF00812361.pdf</idno><date when="1990">1990</date><idno type="doi">10.1007/BF00812361</idno><idno type="wicri:Area/Main/Corpus">000764</idno><idno type="wicri:Area/Main/Curation">000764</idno><idno type="wicri:Area/Main/Exploration">000423</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Colorectal carcinoma</term><term>Fragments</term><term>Indium 111</term><term>Monoclonal antibodies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">Six European nuclear medicine centres per formed immunoscintigraphy first retrospectively in 34 patients using indium-111-labelled carcinoembryonic antigen (CEA)-specific and/or 19-9 F(ab')2 fragments. Results for sensitivity and specificity in tumour sites were 94% and 87%, respectively, for the pelvis and 73% and 100% for the extrahepatic abdomen. A second prospective series concerned 58 other patients previously operated on for colorectal adenocarcinoma (27 colon, 31 rectum). Two-thirds of these patients had a suspected recurrence signalled by an isolated rise in tumour markers, and 46 patients examined by immunoscintigraphy, X-ray computed tomography and ultrasonography were found to have a recurrence (a total of 62 tumour sites). Sensitivity and specificity with immunoscintigraphy were 90% and 97%, respectively, for the pelvis and 62% and 95% for the extrahepatic abdomen. For 29 patients injected with CEA-specific fragments, sensitivity was 90% and specificity 94% for the pelvis. For 25 patients injected with 19-9 fragments, pelvic sensitivity and specificity were 80% and 100%, respectively, whereas sensitivity for the extrahepatic abdomen was only 29% since several cases of peritoneal carcinosis were not visualized. In the prospective series, comparison of the three imaging techniques for all tumour sites (including liver and in 5 cases thorax) gave a sensitivity and specificity of 82% and 91 %, respectively, for immunoscintigraphy, 52% and 95% for X-ray computed tomography and 59% and 100% for ultrasonography. These results thus confirm the advantage of using111In-labelled CEA-specific or 19-9 to visualize and localize recurrences of colorectal cancer.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="82ff69a2aee05b44eef96808434b9037f7654d2a"><titleInfo lang="eng"><title>Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab′)2 fragments</title></titleInfo><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Chetanneau</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Centre René Gauducheau and INSERM Research Unit 211, Quai Moncousu, F-44035, Nantes, France</affiliation></name><name type="personal"><namePart type="given">R. P.</namePart><namePart type="family">Baum</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>J.W. Goethe University Hospital, Theodor-Stern-Kai 7, D-6000, Frankfurt/Main 70, Germany</affiliation></name><name type="personal"><namePart type="given">P. A.</namePart><namePart type="family">Lehur</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Centre René Gauducheau and INSERM Research Unit 211, Quai Moncousu, F-44035, Nantes, France</affiliation></name><name type="personal"><namePart type="given">J. C.</namePart><namePart type="family">Liehn</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Institut J. Godinot, B.P. 171, F-51056, Reims, France</affiliation></name><name type="personal"><namePart type="given">A. C.</namePart><namePart type="family">Perkins</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Queen's Medical Centre, University Hospital, NG7 2UH, Nottingham, UK</affiliation></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Bares</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Technical University, Pauwelsstrasse 30, D-5100, Aachen, Germany</affiliation></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Bourguet</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Centre E. Marquis, 2 rue H. Le Guilloux, F-35033, Rennes, France</affiliation></name><name type="personal"><namePart type="given">J. Y.</namePart><namePart type="family">Herry</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Centre E. Marquis, 2 rue H. Le Guilloux, F-35033, Rennes, France</affiliation></name><name type="personal"><namePart type="given">J. C.</namePart><namePart type="family">Saccavini</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>CIS Bioindustrie, B.P. 32, F-91191, Gif sur Yvette, France</affiliation></name><name type="personal"><namePart type="given">J. F.</namePart><namePart type="family">Chatal</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Centre René Gauducheau and INSERM Research Unit 211, Quai Moncousu, F-44035, Nantes, France</affiliation></name><typeOfResource>text</typeOfResource><genre>Original Article</genre><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateCreated encoding="w3cdtf">1990-02-24</dateCreated><dateValid encoding="w3cdtf">2004-11-29</dateValid><copyrightDate encoding="w3cdtf">1990</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">Six European nuclear medicine centres per formed immunoscintigraphy first retrospectively in 34 patients using indium-111-labelled carcinoembryonic antigen (CEA)-specific and/or 19-9 F(ab')2 fragments. Results for sensitivity and specificity in tumour sites were 94% and 87%, respectively, for the pelvis and 73% and 100% for the extrahepatic abdomen. A second prospective series concerned 58 other patients previously operated on for colorectal adenocarcinoma (27 colon, 31 rectum). Two-thirds of these patients had a suspected recurrence signalled by an isolated rise in tumour markers, and 46 patients examined by immunoscintigraphy, X-ray computed tomography and ultrasonography were found to have a recurrence (a total of 62 tumour sites). Sensitivity and specificity with immunoscintigraphy were 90% and 97%, respectively, for the pelvis and 62% and 95% for the extrahepatic abdomen. For 29 patients injected with CEA-specific fragments, sensitivity was 90% and specificity 94% for the pelvis. For 25 patients injected with 19-9 fragments, pelvic sensitivity and specificity were 80% and 100%, respectively, whereas sensitivity for the extrahepatic abdomen was only 29% since several cases of peritoneal carcinosis were not visualized. In the prospective series, comparison of the three imaging techniques for all tumour sites (including liver and in 5 cases thorax) gave a sensitivity and specificity of 82% and 91 %, respectively, for immunoscintigraphy, 52% and 95% for X-ray computed tomography and 59% and 100% for ultrasonography. These results thus confirm the advantage of using111In-labelled CEA-specific or 19-9 to visualize and localize recurrences of colorectal cancer.</abstract><subject lang="eng"><genre>Key words</genre><topic>Monoclonal antibodies</topic><topic>Fragments</topic><topic>Indium 111</topic><topic>Colorectal carcinoma</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1990</partNumber><partNumber>Volume: 17</partNumber><partNumber>Number: 5</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1990-05-01</dateIssued><copyrightDate encoding="w3cdtf">1990</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 18</identifier><recordInfo><recordOrigin>Springer-Verlag, 1990</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF00812361</identifier><identifier type="matrixNumber">Art5</identifier><identifier type="local">BF00812361</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>223</start><end>229</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1990</recordOrigin><recordIdentifier>259_1990_Article_BF00812361.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000423 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000423 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1990_Article_BF00812361.pdf
|texte= Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab′)2 fragments
}}
| This area was generated with Dilib version V0.5.81. |  |